The following SMFM documents have been withdrawn effective 2024:
Consult Series #40: The role of routine cervical length screening in selected high‐and low‐risk women for preterm birth prevention
Statement #7: The role of cervical pessary placement to prevent preterm birth in clinical practice
The following SMFM documents have been withdrawn effective 2025:
Special Statement: Who's who in patient safety and quality for maternal healthcare in the United States
The following SMFM documents have been replaced effective 2024:
Clinical Guideline #5: Twin‐twin transfusion syndrome
And
Consult Series #24: The importance of determining chorionicity in twin gestations
Replaced by Consult Series #72: Twin‐twin transfusion syndrome and twin anemia‐polycythemia sequence
The following SMFM documents have been replaced effective 2025:
Consult Series #36: Prenatal aneuploidy screening using cell‐free DNA
Replaced by Consult Series #74: Cell‐free DNA screening for aneuploidies: Updated guidance
The following SMFM documents have been reaffirmed effective 2024:
Consult Series #37: Diagnosis and management of vasa previa
Consult Series #41: The use of chromosomal microarray for prenatal diagnosis
Consult Series #42: The role of ultrasound in women who undergo cell‐free DNA screening
Consult Series #44: Management of bleeding in the late preterm period
Consult Series #45: Mild fetal ventriculomegaly: diagnosis, evaluation, and management
Consult Series #46: Evaluation and management of polyhydramnios
Consult Series #51: Thromboembolism prophylaxis for cesarean delivery
Consult Series #52: Diagnosis and management of fetal growth restriction
Consult Series #53: Intrahepatic cholestasis of pregnancy
Consult Series #54: Assessing the risk of maternal morbidity and mortality
Consult Series #55: Counseling women at increased risk of maternal morbidity and mortality
Consult Series #60: Management of pregnancies resulting from in vitro fertilization
Consult Series #61: Anticoagulation in pregnant patients with cardiac disease
Consult Series #62: Best practices in equitable care delivery‐ Addressing systemic racism and other social determinants of health as causes of obstetrical disparities
Consult Series #63: Cesarean scar ectopic pregnancy
Statement #8: Pharmacological treatment of gestational diabetes
Statement #9: Elective induction of labor in low‐risk nulliparous women at term: the ARRIVE trial
Statement #11: Antihypertensive therapy for mild chronic hypertension in pregnancy: The CHAP Trial
Fetal Anomalies Consult Series #3: Intracranial anomalies
Guideline #6: Fetal blood sampling
Guideline #9: Amniotic fluid embolism: diagnosis and management
The following SMFM documents have been reaffirmed effective 2025:
Consult Series #48: Immediate postpartum long‐acting reversible contraception for women at high risk for medical complications
Consult Series #50: The role of activity restriction in obstetric management
Consult Series #57: Evaluation and management of isolated soft ultrasound markers for aneuploidy in the second trimester
Consult Series #58: Use of antenatal corticosteroids for individuals at risk for late preterm delivery
Consult Series #59: The use of analgesia and anesthesia for maternal‐fetal procedures
Consult Series #64: Systemic lupus erythematosus in pregnancy
Consult Series #65: Transabdominal cerclage
Consult Series #66: Prepregnancy evaluation and pregnancy management of patients with solid organ transplants
Consult Series #67: Maternal sepsis
Statement: Response to the Food and Drug Administration's withdrawal of 17‐alpha hydroxyprogesterone caproate
Fetal Anomalies Consult Series #1: Facial anomalies
Guideline #8: The fetus at risk for anemia–diagnosis and management
Amniocentesis or chorionic villous sampling (CVS) checklist (online‐only)
Special Statement: Surgical safety checklists for cesarean delivery
Special Statement: A maternal transport briefing form and checklist
Special Statement: Operative vaginal delivery: Checklists for performance and documentation
Special Statement: Postpartum visit checklists for normal pregnancy and complicated pregnancy
Special Statement: Checklist for pregnancies resulting from in vitro fertilization
Special Statement: Checklists for transabdominal cerclage
Special Statement: Prophylactic low‐dose aspirin for preeclampsia prevention—quality metric and opportunities for quality improvement
Special Statement: Quality metrics for optimal timing of antenatal corticosteroid administration
Special Statement: Quality metric for timely postpartum follow‐up after severe hypertension
Special Statement: A quality metric for evaluating timely treatment of severe hypertension
Special Statement: Telemedicine in obstetrics—quality and safety considerations
Special Statement: Quality metric on the rate of postpartum diabetes screening after pregnancies with gestational diabetes mellitus
Special Statement: Checklist for thromboembolism prophylaxis after cesarean delivery
Special Statement: Checklist for postpartum discharge of women with hypertensive disorders
Special Statement: A critique of postpartum readmission rate as a quality metric
Special Statement: Cognitive bias and medical error in obstetrics—challenges and opportunities
Special Statement: Curriculum outline on patient safety and quality for maternal‐fetal medicine fellows
Special Statement: A critical examination of abortion terminology as it relates to access and quality of care
All current SMFM clinical guidance can be accessed at www.smfm.org/publications.